Alt tag
Alt tag

參考資料

  1. Guillebaud J. The Pill and Other Forms of Hormonal Contraception. Oxford University Press; 2004.
  2. Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70(3):191-198.
  3. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception. 2008;78(1):16-25.
  4. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61(2):105-111.
  5. Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ethinylestradiol 3 mg/20 μg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs. 2007;67(12):1749-1765.
  6. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62(1):29-38.
  7. YAZ [package insert]. Bayer HealthCare Hong Kong; March 2020.
  8. Szarewski A, Guillebaud J. Contraception: A User's Guide. 3rd ed. Oxford University Press; 2001.
  9. Hernádi L, Marr J, Trummer D, De Leo V, Petraglia F. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception. 2009;80(1):18-24.
  10. Leridon H. Can assisted reproduction technology compensate for the natural decline in fertility with age? A model assessment. Hum Reprod. 2004;19(7):1548-1553.
  11. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404.
  12. IQVIA research data G03A – Hormonal Contracept Syst. MAT Q4 2025 (Sales Value) with channel breakdown.
  13. Cronin M, Schellschmidt I, Dinger J. Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives. Obstet Gynecol. 2009;114(3):616-622.
  14. Jellesen R, Møller LF, Nøhr EA, et al. Time trends in oral contraceptive use and risk of birth defects in Denmark. Paediatr Perinat Epidemiol. 2008;22(4):334-340.
  15. World Health Organization, Johns Hopkins Bloomberg School of Public Health, Center for Communication Programs. Family Planning: A Global Handbook for Providers. 2022 update. World Health Organization; 2022.
  16. Dinger J, Möhner S, Minh TD, Westhoff C. Myocardial infarction and ischemic stroke in users of drospirenone-containing oral contraceptives. Contraception. 2016;93(5):378-385.
  17. Dinger JC, Heinemann LAJ, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on Oral Contraceptives. Obstet Gynecol. 2011;117(1):33-40.
  18. Oral contraceptives. JAMA. 2014;311(3):321.
  19. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(suppl 1):S7-S16.
  20. Endrikat JS, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B. A comparative study of cycle control, tolerability and efficacy of two low-dose oral contraceptives containing drospirenone. Contraception. 2009;79(6):428-432.
  21. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 μg versus >20 μg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;(8):CD003989.
  22. Yasmin [package insert]. Bayer HealthCare Ltd Hong Kong; March 2020.
  23. US Food and Drug Administration. FDA Drug Safety Communication: updated information about the risk of blood clots in women taking birth control pills containing drospirenone. Accessed May 19,2026.  https://web.archive.org/web/20260303204857/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-information-about-risk-blood-clots-women-taking-birth-control
  24. YAZ xCCDS. Version 19. 2023:5.
  25. Loudon N. Starting on the pill. Br Med J. 1977;2(6085):521-522.
  26. Philips C, et al. Starting on the pill. Br Med J. 1978;2(6143):1021-1022.
  27. Taylor D, et al. Contraception. 1986;33(5):463-471.
  28. Yasmin xCCDS. Version 18. 2023:5.
  29. Burkman R, et al. Am J Obstet Gynecol. 2004;190(4).
  30. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies. Lancet. 2008;371(9609):303-314.
  31. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27,276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16(9):1061-1070.
  32. Asthana S, et al. Effect of oral contraceptive use on risk of cervical cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;247:163-175.
  33. Smith JS, Green J, Berrington de González A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361(9364):1159-1167.
  34. American Cancer Society. Cervical Cancer Causes, Risk Factors, and Prevention. Accessed May 19, 2026.  https://www.cancer.org/cancer/types/cervical-cancer/causes-risks-prevention.html
  35. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228-2239.
  36. Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007;47(4):506-513.
  37. McGlynn KA, Sahasrabuddhe VV, Campbell PT, et al. Reproductive factors, exogenous hormone use and risk of liver cancer among US women: results from the Liver Cancer Pooling Project. Br J Cancer. 2015;112(7):1266-1272.
  38. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol. 2017;216(6):580.e1-580.e9.




 

*服務只提供予香港及澳門特別行政區客戶   
查詢服務時間:星期一至五 早上9時至12時; 下午1時至5時半
不是每位女性都適合服用口服避孕藥。如果妳有以下情況，請勿服用混合式口服避孕藥：35歲以上吸煙女士；腎臟或肝臟問題；血液凝固或栓塞病病史；癌症；心臟病或中風；懷孕。混合式口服避孕藥在罕有情況下可能會增加血凝塊、中風及心臟病的風險。選擇YAZ®優悅®或Yasmin®優思明®前，請向妳的醫生或醫護人員查詢。   
如服用後出現不常見的狀況如腿部疼痛或紅腫、胸口不適、視力有影響、呼吸困難、黃疸等症狀，請立即停藥並聯絡妳的醫生。避孕藥不能夠預防性傳播疾病，包括愛滋病毒/愛滋病。   
詳情請參閱常見問題。

若妳要報告產品的副作用或對質素作出投訴，請聯絡妳的醫療保健顧問（如醫生或藥劑師）或當地的醫療監管機構。妳亦可致電產品熱線 (852) 8100 2755或電郵至drugsafety.hk@bayer.com。 (網上表格僅限英文 https://pharma.bayer.com/report-side-effect )

If you want to report a side effect or quality complaint, please contact your healthcare professional (e.g. physician or pharmacist) or your local Health Authority. Inquiries can also be directed to hotline: (852) 8100 2755 or email: drugsafety.hk@bayer.com
Copyright© Bayer HealthCare Limited PP-YSM-HK-0105-1, PP-YSM-HK-0091-1
*網站最後更新於 10-03-2026 本網站為香港居民適用

*服務只提供予香港及澳門特別行政區客戶   
查詢服務時間:星期一至五 早上9時至12時; 下午1時至5時半
不是每位女性都適合服用口服避孕藥。如果妳有以下情況，請勿服用混合式口服避孕藥：35歲以上吸煙女士；腎臟或肝臟問題；血液凝固或栓塞病病史；癌症；心臟病或中風；懷孕。混合式口服避孕藥在罕有情況下可能會增加血凝塊、中風及心臟病的風險。選擇YAZ®優悅®或Yasmin®優思明®前，請向妳的醫生或醫護人員查詢。   
如服用後出現不常見的狀況如腿部疼痛或紅腫、胸口不適、視力有影響、呼吸困難、黃疸等症狀，請立即停藥並聯絡妳的醫生。避孕藥不能夠預防性傳播疾病，包括愛滋病毒/愛滋病。   
詳情請參閱常見問題。
 
若妳要報告產品的副作用或對質素作出投訴，請聯絡妳的醫療保健顧問（如醫生或藥劑師）或當地的醫療監管機構。妳亦可致電產品熱線 (852) 8100 2755或電郵至drugsafety.hk@bayer.com。 (網上表格僅限英文 https://pharma.bayer.com/report-side-effect )
 
If you want to report a side effect or quality complaint, please contact your healthcare professional (e.g. physician or pharmacist) or your local Health Authority. Inquiries can also be directed to hotline: (852) 8100 2755 or email: drugsafety.hk@bayer.com
一般使用條款 | 私隱聲明 | 出版說明 | 聯絡我們 |   
如何購買 | 參考資料
Copyright© Bayer HealthCare Limited   
PP-YSM-HK-0105-1, PP-YSM-HK-0091-1
*網站最後更新於 10-03-2026 本網站為香港居民適用